Literature DB >> 16007578

cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary tumours and alteration in genes coding for components of energy metabolism occurs with increasing grade.

Leida B Rozeman1, Liesbeth Hameetman, Tom van Wezel, Antonie H M Taminiau, Anne Marie Cleton-Jansen, Pancras C W Hogendoorn, Judith V M G Bovée.   

Abstract

Conventional central chondrosarcomas are malignant cartilaginous tumours, occasionally arising secondary to either solitary or multiple (Ollier disease) enchondromas. Recurrences may have progressed in grade. The aims of the present study were to identify putative differences in gene expression between solitary and Ollier disease-related tumours, and to elucidate signalling pathways involved in tumour progression by genome-wide cDNA expression analysis. Arrays enriched for cartilage-specific cDNAs and genes involved in general tumourigenesis were used to analyse enchondromas (n = 3, two with Ollier disease), chondrosarcomas of different grades (n = 19, three with Ollier disease), normal resting-zone cartilage (n = 2), and chondrosarcoma cells in culture (n = 7). The arrays were analysed by unsupervised hierarchical clustering, significant analysis of microarray, and T-tests. Confirmation of data was performed by immunohistochemistry and quantitative reverse transcriptase polymerase chain reaction (RT-PCR). Ollier disease cases and solitary tumours revealed similar expression profiles, suggesting that the same signalling pathways are involved in tumourigenesis. Interestingly, JunB protein expression was significantly higher in grade I chondrosarcomas than in enchondromas (p = 0.009), which could be of diagnostic relevance. Upon chondrosarcoma progression, matrix-associated genes are down-regulated, reflecting the histology of high-grade tumours. An increase in glycolysis-associated, and a decrease in oxidative phosphorylation-related, genes was found in high-grade tumours. These findings suggest an adaptation in energy supply upon progression towards higher grade. Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16007578     DOI: 10.1002/path.1813

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  14 in total

Review 1.  Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn; Jay S Wunder; Benjamin A Alman
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

Review 2.  Genetic alterations in chondrosarcomas - keys to targeted therapies?

Authors:  Andre M Samuel; Jose Costa; Dieter M Lindskog
Journal:  Cell Oncol (Dordr)       Date:  2014-01-24       Impact factor: 6.730

Review 3.  Enchondromatosis: insights on the different subtypes.

Authors:  Twinkal C Pansuriya; Herman M Kroon; Judith V M G Bovée
Journal:  Int J Clin Exp Pathol       Date:  2010-06-26

4.  Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma.

Authors:  Yvonne M Schrage; Liesbeth Hameetman; Karoly Szuhai; Anne-Marie Cleton-Jansen; Antonie H M Taminiau; Pancras C W Hogendoorn; Judith V M G Bovée
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

5.  Translocase of the outer mitochondrial membrane complex subunit 20 (TOMM20) facilitates cancer aggressiveness and therapeutic resistance in chondrosarcoma.

Authors:  Megan E Roche; Zhao Lin; Diana Whitaker-Menezes; Tingting Zhan; Karoly Szuhai; Judith V M G Bovee; John A Abraham; Wei Jiang; Ubaldo Martinez-Outschoorn; Atrayee Basu-Mallick
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-09-10       Impact factor: 5.187

6.  Putative multifunctional signature of lung metastases in dedifferentiated chondrosarcoma.

Authors:  Sergey Malchenko; Elisabeth A Seftor; Yuri Nikolsky; Susan L Hasegawa; Sean Kuo; Jeff W Stevens; Stas Poyarkov; Tatiana Nikolskaya; Tamara Kucaba; Min Wang; Hakim Abdulkawy; Thomas Casavant; Jose Morcuende; Joseph Buckwalter; Raymond Hohl; Barry Deyoung; Kemp Kernstine; Maria de Fatima Bonaldo; Mary J C Hendrix; Marcelo B Soares; Vera Maria F C Soares
Journal:  Sarcoma       Date:  2012-02-16

7.  Macrodissection versus microdissection of rectal carcinoma: minor influence of stroma cells to tumor cell gene expression profiles.

Authors:  Elza C de Bruin; Simone van de Pas; Esther H Lips; Ronald van Eijk; Minke M C van der Zee; Marcel Lombaerts; Tom van Wezel; Corrie A M Marijnen; J Han J M van Krieken; Jan Paul Medema; Cornelis J H van de Velde; Paul H C Eilers; Lucy T C Peltenburg
Journal:  BMC Genomics       Date:  2005-10-14       Impact factor: 3.969

8.  BMP and TGFbeta pathways in human central chondrosarcoma: enhanced endoglin and Smad 1 signaling in high grade tumors.

Authors:  Stephane Boeuf; Judith V M G Bovée; Burkhard Lehner; Brendy van den Akker; Maayke van Ruler; Anne-Marie Cleton-Jansen; Wiltrud Richter
Journal:  BMC Cancer       Date:  2012-10-22       Impact factor: 4.430

9.  Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation.

Authors:  K H Hallor; J Staaf; G Jönsson; M Heidenblad; F Vult von Steyern; H C F Bauer; M Ijszenga; P C W Hogendoorn; N Mandahl; K Szuhai; F Mertens
Journal:  Br J Cancer       Date:  2007-12-11       Impact factor: 7.640

10.  Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix.

Authors:  Stefan M Willems; Alex B Mohseny; Crina Balog; Raj Sewrajsing; Inge H Briaire-de Bruijn; Jeroen Knijnenburg; Anne-Marie Cleton-Jansen; Raf Sciot; Christopher D M Fletcher; André M Deelder; Karoly Szuhai; Paul J Hensbergen; Pancras C W Hogendoorn
Journal:  J Cell Mol Med       Date:  2009-03-13       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.